Department of Medical Biochemistry, Ismailia, Egypt.
Cancer Biomark. 2010;7(3):163-70. doi: 10.3233/CBM-2010-0186.
BACKGROUND/AIM: Proepithelin is a growth factor that may play a critical role in bladder cancer. Its over-expression in urine of bladder cancer patients gave us the impetus to evaluate its potential suitability as a biomarker for bladder cancer diagnosis and/or prognosis.
proepithelin was estimated in 86 voided urine samples, including 59 bladder cancer patients and 27 healthy volunteers using quantitative sandwich enzyme immunoassay technique. Urinary proepithelin level was expressed in ng/100 mg creatinine.
Urinary proepithelin was significantly higher in bladder cancer patients compared to control subjects (means: 17.5 ± 10 and 8.9 ± 3.5 ng/100 mg creatinine, respectively; p < 0.001), and the test sensitivity and specificity to detect the presence of bladder cancer were 74.6 and 85.2%, respectively. Furthermore, patients with low-grade/non-muscle invasive stages bladder cancer showed significantly lower urinary proepithelin compared to high-grade/non-muscle invasive stages and high-grade/invasive stages ones (means: 11.6 ± 9, 20.2 ± 8.1 and 23.8 ± 11.9 ng/100 mg creatinine, respectively; p= 0.005 and 0.002, respectively).
This preliminary study suggests that urinary proepithelin may be considered as a non-invasive, sensitive, and specific urine-based test for bladder cancer diagnosis and/or prognosis.
背景/目的：原促表皮素是一种生长因子，可能在膀胱癌中发挥关键作用。它在膀胱癌患者尿液中的过度表达促使我们评估其作为膀胱癌诊断和/或预后的生物标志物的潜在适用性。
采用定量夹心酶免疫分析法检测 86 例尿样中的原促表皮素，包括 59 例膀胱癌患者和 27 例健康志愿者。尿中原促表皮素水平以 ng/100mg 肌酐表示。
膀胱癌患者的尿中原促表皮素水平明显高于对照组（平均值分别为 17.5±10 和 8.9±3.5ng/100mg 肌酐；p<0.001），检测膀胱癌存在的检测灵敏度和特异性分别为 74.6%和 85.2%。此外，低级别/非肌层浸润性膀胱癌患者的尿中原促表皮素水平明显低于高级别/非肌层浸润性和高级别/浸润性膀胱癌患者（平均值分别为 11.6±9、20.2±8.1 和 23.8±11.9ng/100mg 肌酐；p=0.005 和 0.002）。
这项初步研究表明，尿中原促表皮素可作为一种非侵入性、敏感、特异的膀胱癌诊断和/或预后的尿液检测方法。
